BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$0.66 – $0.825
Volume13,156
Market cap$2M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.41M
Price / earnings
—
Price / book
0.31×
Price / sales
0.77×
EV / sales
0.39×
EV / EBITDA
-0.45×
Profitability
Earnings per share
-$0.88
Return on assets
-29.51%
Return on equity
-33.11%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
6.08×
Quick ratio
5.28×
Cash ratio
1.52×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$853.6K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BGLC, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$76.16K
$22.84K
$483.76K
$2.54M
$2.26M
$2.14M
$2.52M
$2.63M
Cost of revenue
$63.17K
$23.63K
$487.74K
$2.17M
$1.89M
$1.79M
$2.21M
$2.3M
Gross profit
$12.98K
-$790
-$3.98K
$377.69K
$368.02K
$343.49K
$309.23K
$326.54K
Selling, general and administrative
$334.55K
$380.4K
$1.01M
$997.26K
$1.13M
$932.57K
$801.8K
$2.04M
Research and development
$13.67K
$14.49K
$11.1K
$14.88K
$12.56K
$12.14K
$17.4K
$10.44K
Total operating expenses
$416.38K
$570.64K
$1.08M
$1.19M
$1.14M
$959.68K
$1.58M
$2.05M
Operating income
-$403.4K
-$571.43K
-$1.08M
-$810.27K
-$769.75K
-$616.19K
-$1.27M
-$1.72M
Interest expense
-$4.06K
-$3.09K
-$3.27K
-$6.48K
-$4.88K
-$4.91K
-$5.81K
-$6.19K
Income before taxes
-$286.45K
-$543.58K
-$1.04M
-$708.99K
-$616.17K
-$623.33K
-$422.03K
-$1.34M
Income taxes
$0
$0
$0
$0
$0
$0
-$73.71K
$1.56K
Net income
-$286.45K
-$543.58K
-$1.04M
-$708.99K
-$616.17K
-$623.33K
-$348.32K
-$1.35M
Net income attributable to common shareholders
-$286.45K
-$543.58K
-$1.04M
-$708.99K
-$616.17K
-$623.33K
-$348.32K
-$1.35M
EBITDA
-$375.34K
-$543.14K
-$1.05M
-$781.27K
-$741.95K
-$589.55K
-$1.24M
-$1.69M
Basic earnings per share
-$0.12
-$0.23
-$0.51
-$0.40
-$0.34
-$0.35
-$0.01
-$0.75
Diluted earnings per share
-$0.12
-$0.23
-$0.51
-$0.40
-$0.34
-$0.35
-$0.01
-$0.75
Recent news
Company coverage with links to the original publishers.
Ruanyun Edai Technology Inc. (NASDAQ: RYET) has signed a definitive agreement to grant BioNexus Gene Lab Corp. (NASDAQ: BGLC) an exclusive 10-20 year license for its Cogni AI document-intelligence platform in Malaysian healthcare. RYET will receive 560,000 BGLC shares and a 10% royalty on qualifying technology receipts. The deal aligns with Malaysia's RM1 billion healthcare digitalization initiative, though neither company has secured government contracts yet.
BioNexus Gene Lab Corp entered a strategic partnership with BirchBioMed Inc. to invest $10 million and collaborate on advancing FS2 topical platform in Southeast Asia, focusing on dermal regeneration and fibrosis control.
BioNexus Gene Lab Corp. (BGLC) filed its 2024 annual report, showcasing strategic realignment, technological advancement, and improved financial performance. The company highlighted its blockchain-native treasury strategy, expansion of genomic diagnostics offerings, and partnerships to scale its AI-based health diagnostics initiatives.
KUALA LUMPUR, Malaysia, April 20, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corporation (NASDAQ: BGLC), peneraju global dalam diagnostik genomik dan teknologi penjagaan kesihatan, mengumumkan pelaburan strategik melalui anak syarikat milik penuh mereka, MRNA Scientific Sdn Bhd, dalam Ascension Innovation Sdn Bhd (AISB), sebuah syarikat persendirian di Malaysia. Pelaburan ini menegaskan komitmen BGLC dalam memajukan penyelesaian penjagaan kesihatan menerusi AI dan analisis ramalan termaju.